Silo Pharma Inc
For the period ended Nov 12, 2024. Filed Sep 18, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Nov 12, 2024 · Filed Sep 18, 2024
Contents
Pay Versus Performance Table
| Year(1) | SummaryCompensationTable Totalfor PEO | CompensationActually Paidto PEO(2) | AverageSummaryCompensationTable Totalfor Non-PEONEOs | AverageCompensationActuallyPaid toNon-PEONEOs(2) | Value ofInitial Fixed$100 InvestmentBased OnTotalShareholderReturn | NetIncome(Loss) |
|---|---|---|---|---|---|---|
| (a) | (b) | (c) | (d) | (e) | (f) | (h) |
| 2023 | $569,009 | $569,009 | $62,692 | $62,692 | 6.79 | $(3,700,683) |
| 2022 | $332,250 | $332,250 | $15,000 | $15,000 | 15.83 | $(3,908,551) |
| 2021 | $345,000 | $345,000 | $0 | $0 | 33.57 | $3,903,741 |
(1) The PEO (CEO) in the 2023, 2022 and 2021 reporting year is Eric Weisblum. The non-PEO NEOs in the 2023 and 2022 reporting year is Dan Ryweck.
(2) The CAP was calculated beginning with the PEO’s SCT total. No amounts were deducted from or added to the applicable SCT total compensation. Since all equity awards were fully vested prior to 2021, no reconciliation to with respect to equity awards for summary compensation numbers was required.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.